C. Graux MD, PhD

O.5 Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): an interim analysis from the Belgian Hematology Society (BHS)

Highlights in acute myeloid leukemia (AML): what is going to change?

SUMMARY

The decision making process in AML integrates clinical features, an increasing amount of genetic information and minimal residual disease (MRD) data. Combining these data aims at answering the following questions:

• do I treat my patient with an intensive (= curative) or a non intensive (= non-curative) approach ?
• do I have therapeutic targets to improve the current treatment?
• is there an indication for a stem cell transplantation (SCT), maintenance therapy, etc.

Each new edition of ASH brings some new answers. This was again the case at the 2016 annual ASH meeting.

(BELG J HEMATOL 2017;8(1):29–33)

O.5 BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review and meta-analysis on the risk of cardiovascular events, major molecular response and overall survival

PP4.2 The clinical relevance of imatinib (Im) plasma trough concentration in patients with chronic myelocytic leukemia (CML) in chronic phase. A Belgian retrospective study

P1.11 Retrospective Chart Review of Hospitalisations and Costs Associated with the Treatment of Adults with Philadelphia-negative (-) B-precursor Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) in Belgium

BHS 2013 recommendations for treatment of myelodysplastic syndromes

Summary

The guidelines on the current state-of-the-art in the diagnosis and treatment of myelodysplastic syndromes of the Belgian Hematological Society working group on myelodysplastic syndromes were published in 2013.¹ The key points of these guidelines are presented in two issues of the Belgian Journal of Hematology. In this paper we present the optimal treatment of patients with myelodysplastic syndromes within the current limitations of Belgian reimbursement modalities.

(BELG J HEMATOL 2015;6(2):54–60)

The 2013 Belgian Hematological Society recommendations for the diagnosis and classification of myelodysplastic syndromes

Summary

The Belgian Hematological Society working group on myelodysplastic syndromes published their guidelines on the state of the art in diagnosis and treatment of myelodysplastic syndromes and the key points of these recommendations are presented in two issues of the Belgian Journal of Hematology.¹ In this first paper we present the requirements for a correct diagnosis and classification of patients with myelodysplasia.

(BELG J HEMATOL 2015;6(1):10–5)